<?xml version="1.0" encoding="UTF-8"?>
<p>Implementation of guidelines changes, like the introduction of TDF-3TC-EFV are likely to happen every few years, as evidence for better treatment becomes available. Supply chain problems at scale-up and decentralisation of ART have been documented before [
 <xref rid="pone.0191294.ref029" ref-type="bibr">29</xref>]. In South Africa, facility stockouts also increased during introduction of TDF-3TC-EFV as a first-line regimen in 2013 and there was a national stockout of second-line regimens in 2015 due to unanticipated scale-up [
 <xref rid="pone.0191294.ref030" ref-type="bibr">30</xref>]. As such critical periods for the management of supply chains will continue to occur at introduction of new ART regimens, the need for engagement of all actors, extensive supply planning and firm orders has been suggested [
 <xref rid="pone.0191294.ref031" ref-type="bibr">31</xref>, 
 <xref rid="pone.0191294.ref032" ref-type="bibr">32</xref>]. In DRC, introduction of rapidly changing WHO recommendations for superior drug regimens needs to be accompanied by similar preparation.
</p>
